ALLMedicine™ Acute Promyelocytic Leukemia Center
Research & Reviews 923 results
https://doi.org/10.1182/bloodadvances.2021004966
Blood Advances; Miltiadous O, Petrova-Drus K et. al.
Sep 23rd, 2021 - FIP1L1-RARA associated neoplasm is a very rare and aggressive disease, with only 3 previously reported cases in the literature. Herein we describe a 9-month-old boy who presented with a FIP1L1-RARA fusion associated myelodysplastic/myeloproliferat...
https://doi.org/10.1007/s12185-021-03224-5 10.1158/2159-8290.CD-19-1011 10.1073/pnas.77.5.2936 10.1080/15384101.2020.1810402 10.3390/cancers11121915 10.3390/cells9091921 10.1182/blood-2005-10-4202 10.1182/blood-2009-08-236588 10.3324/haematol.13378 10.1007/s00277-016-2810-z 10.1182/blood-2016-08-733196 10.1038/s41408-019-0241-5 10.1016/j.cell.2016.08.057 10.3109/10428194.2013.876633 10.1074/jbc.RA119.009396 10.1186/s12885-020-07533-6 10.1084/jem.20150736 10.1182/blood-2015-05-646786 10.3324/haematol.2019.230482 10.1080/10428190801959018 10.1182/blood-2014-11-612416 10.1182/blood-2014-11-611459 10.1038/s41375-019-0697-0 10.3324/haematol.2020.264432 10.3390/biomedicines8100385 10.1182/blood-2015-07-653840 10.1038/bcj.2014.25 10.1016/j.bbrc.2012.09.131 10.1182/blood.V90.7.2591 10.1111/j.1365-2141.2006.06014.x 10.1016/j.biopha.2020.109878 10.1200/JCO.19.01053
International Journal of Hematology; Dembitz V, Lalic H et. al.
Sep 22nd, 2021 - All-trans retinoic acid (ATRA)-based therapy for acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML), is the most successful example of differentiation therapy. Although ATRA can induce differentiation in some non-APL AML...
https://doi.org/10.1093/ajcp/aqab137
American Journal of Clinical Pathology; Asadbeigi S, Zhou Y
Sep 22nd, 2021 - Acute promyelocytic leukemia (APL) requires emergent treatment while definitive laboratory results are pending. Following the death of a patient whose diagnosis was delayed, we sought to improve our institution's workflow by using the EPIDEM (Expl...
https://doi.org/10.1182/bloodadvances.2021004649
Blood Advances; Efficace F, Platzbecker U et. al.
Sep 17th, 2021 - The main objective of this study was to compare the long-term health-related quality of life of patients with acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) versus ATRA plus standard chem...
https://doi.org/10.1002/cncr.33914
Cancer Jamy OH, Dhir A et. al.
Sep 9th, 2021 - The survival of patients with acute promyelocytic leukemia (APL) has dramatically improved with the use of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). However, because of the complexity of the initial management, early mortality (EM...
Guidelines 1 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161234
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.
Sep 14th, 2013 - These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocyt...
Drugs 11 results see all →
News 53 results
https://decisionpoint.medscape.com/oncology/viewarticle/936167
Sep 18th, 2020 - This transcript has been edited for clarity. Differentiation syndrome is a frequent complication while patients have active acute promyelocytic leukemia (APL). First of all, we need to mention that the diagnosis of differentiation syndrome is base...
https://www.medscape.com/viewarticle/934124
Jul 17th, 2020 - The estimated one third of patients with acute promyelocytic leukemia (APL) who are older than 60 years of age now enjoy a notably better prognosis than in years past, thanks to the introduction of all-trans retinoic acid (ATRA) and arsenic trioxi...
https://www.medscape.com/viewarticle/917519
Aug 30th, 2019 - While leading his team on a hospital round, Joshua F. Zeidner, MD, saw a note recommending that arsenic trioxide (Trisenox, Teva) should be temporarily discontinued in a 44-year-old woman with acute promyelocytic leukemia (APL). The recommendation...
https://www.staging.medscape.com/viewarticle/917519
Aug 30th, 2019 - While leading his team on a hospital round, Joshua F. Zeidner, MD, saw a note recommending that arsenic trioxide (Trisenox, Teva) should be temporarily discontinued in a 44-year-old woman with acute promyelocytic leukemia (APL). The recommendation...
https://www.mdedge.com/hematology-oncology/article/190803/leukemia-myelodysplasia-transplantation/fda-approves-generic-drugs-apl?channel=50519
HT Staff
Nov 16th, 2018 - Photo from Business Wire Fresenius Kabi’s arsenic trioxide The U. S.
